STADA Arzneimittel's 2021 above-market development

Germany’s STADA Arzneimittel (SAZ: Xetra) outperformed the market again in 2021, overcoming challenging trading conditions to report 8% sales growth to 3.25 billion euros ($3.59 billion) and a 37% increase in profit as earnings before interest, tax, depreciation and amortization (EBITDA) to 776.5 million euros, the company announced today.

All three of the group’s strategic product segments – Specialty, Consumer Healthcare and Generics – contributed to the sales rise, which accelerated especially during the second half of last year as market demand recovered. The group’s diverse product portfolio and broad geographic set-up enabled STADA to meet the needs of several healthcare stakeholders whilst contributing to resilience amid COVID-related market turbulence.

“I am proud and appreciative of how our 12,500 employees around the world have worked tirelessly with our supply-chain partners to ensure that medicines reach patients,” stated STADA’s chief executive, Peter Goldschmidt, adding: “By growing ahead of market averages,” Goldschmidt continued, “STADA was able to generate the cash necessary to continue investing in our people, portfolio and pipeline for the future. Our purpose Caring for People’s Health as a Trusted Partner means always providing patients with the medicines they need, even amid crises and conflicts.”